Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18241788 | 0.89 | HDAC1 (0.54) | HDAC1MEN1KMT2AHSD17B10ACHE | |
| SCHEMBL25242597 | 0.83 | KMT2A (0.56) | HDAC1MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL26441706 | 0.83 | HDAC1 (0.70) | HDAC1MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL18241796 | 0.81 | ACHE (0.43) | HDAC1MEN1KMT2AHSD17B10ACHE | |
| SCHEMBL19085033 | 0.81 | SHBG (0.48) | HDAC1MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL18241812 | 0.80 | HDAC1 (0.45) | HDAC1MEN1KMT2AHSD17B10ACHE | |
| SCHEMBL29215682 | 0.80 | ALDH1A1 (0.54) | HDAC1MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL11211367 | 0.80 | MAPT (0.56) | HDAC1MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL1758260 | 0.78 | KMT2A (0.51) | HDAC1MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL29748711 | 0.78 | HSD17B1 (0.59) | HSD17B10ACHESNCAKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | Kazia Therapeutics Limited (AU) | 2019-08-06 | — | — | US | disclosed |
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Kazia Therapeutics Limited (AU) | 2018-05-24 | — | — | US | disclosed |
| EP-2953938-B1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Novogen ltd (AU) | 2017-08-02 | — | — | EP | disclosed |
| US-9701655-B2 | Functionalised benzopyran compounds and use thereof | NOVOGEN LIMITED (AU) | 2017-07-11 | — | — | US | disclosed |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | VIVESTO AB (SE) | 2016-11-24 | — | — | US | disclosed |
| EP-2953938-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Novogen Ltd. (AU) | 2015-12-16 | — | — | EP | disclosed |
| WO-2015117202-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | NOVOGEN LIMITED (AU) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, BRAP, EP300 | HDAC1 130/4885MEN1 7/4885KMT2A 1486/4885 |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, VHL, NQO1 | HDAC1 218/4885MEN1 2754/4885KMT2A 539/4885 |
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | BRCA1, BRAP, EP300 | HDAC1 130/4885MEN1 7/4885KMT2A 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.